EGFR and non-small cell lung carcinoma: We reviewed the EGFR and KRAS mutation status in TCGA-NSCLC dataset, and found that the mutation frequencies of EGFR and KRAS in stage 1 patients were only 10.2% and 5.7%, respectively, which were lower than advanced stage according to literature reports [25,26].